213 related articles for article (PubMed ID: 24700358)
1. Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4.
Tian X; Langkilde AE; Thorolfsson M; Rasmussen HB; Vestergaard B
J Pharm Sci; 2014 Jun; 103(6):1701-10. PubMed ID: 24700358
[TBL] [Abstract][Full Text] [Related]
2. High concentration formulation studies of an IgG2 antibody using small angle X-ray scattering.
Mosbæk CR; Konarev PV; Svergun DI; Rischel C; Vestergaard B
Pharm Res; 2012 Aug; 29(8):2225-35. PubMed ID: 22477029
[TBL] [Abstract][Full Text] [Related]
3. Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering.
Law-Hine D; Rudiuk S; Bonestebe A; Ienco R; Huille S; Tribet C
Mol Pharm; 2019 Dec; 16(12):4902-4912. PubMed ID: 31618040
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.
Skamris T; Tian X; Thorolfsson M; Karkov HS; Rasmussen HB; Langkilde AE; Vestergaard B
Pharm Res; 2016 Mar; 33(3):716-28. PubMed ID: 26563206
[TBL] [Abstract][Full Text] [Related]
5. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
[TBL] [Abstract][Full Text] [Related]
6. The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions.
Hui GK; Gardener AD; Begum H; Eldrid C; Thalassinos K; Gor J; Perkins SJ
J Biol Chem; 2019 Jul; 294(28):10789-10806. PubMed ID: 31088911
[TBL] [Abstract][Full Text] [Related]
7. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.
Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K
Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240
[TBL] [Abstract][Full Text] [Related]
8. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
[TBL] [Abstract][Full Text] [Related]
9. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
[TBL] [Abstract][Full Text] [Related]
10. Subclass Effects on Self-Association and Viscosity of Monoclonal Antibodies at High Concentrations.
Chowdhury AA; Manohar N; Witek MA; Woldeyes MA; Majumdar R; Qian KK; Kimball WD; Xu S; Lanzaro A; Truskett TM; Johnston KP
Mol Pharm; 2023 Jun; 20(6):2991-3008. PubMed ID: 37191356
[TBL] [Abstract][Full Text] [Related]
11. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
[TBL] [Abstract][Full Text] [Related]
12. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
14. In-depth analysis of subclass-specific conformational preferences of IgG antibodies.
Tian X; Vestergaard B; Thorolfsson M; Yang Z; Rasmussen HB; Langkilde AE
IUCrJ; 2015 Jan; 2(Pt 1):9-18. PubMed ID: 25610623
[TBL] [Abstract][Full Text] [Related]
15. Conformational Plasticity of the Immunoglobulin Fc Domain in Solution.
Remesh SG; Armstrong AA; Mahan AD; Luo J; Hammel M
Structure; 2018 Jul; 26(7):1007-1014.e2. PubMed ID: 29731233
[TBL] [Abstract][Full Text] [Related]
16. The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity.
Knight MJ; Floret L; Patel N; O'Hara J; Rodriguez E
MAbs; 2022; 14(1):2127172. PubMed ID: 36198003
[TBL] [Abstract][Full Text] [Related]
17. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.
Neergaard MS; Kalonia DS; Parshad H; Nielsen AD; Møller EH; van de Weert M
Eur J Pharm Sci; 2013 Jun; 49(3):400-10. PubMed ID: 23624326
[TBL] [Abstract][Full Text] [Related]
18. Biophysical Characterization of Binary Therapeutic Monoclonal Antibody Mixtures.
Krieg D; Berner C; Winter G; Svilenov HL
Mol Pharm; 2020 Aug; 17(8):2971-2986. PubMed ID: 32687367
[TBL] [Abstract][Full Text] [Related]
19. Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies.
Thakkar SV; Sahni N; Joshi SB; Kerwin BA; He F; Volkin DB; Middaugh CR
Protein Sci; 2013 Oct; 22(10):1295-305. PubMed ID: 23893936
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of the multistep aggregation mechanism of monoclonal antibodies.
Nicoud L; Arosio P; Sozo M; Yates A; Norrant E; Morbidelli M
J Phys Chem B; 2014 Sep; 118(36):10595-606. PubMed ID: 25119992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
